Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 52, Issue 11, 2011, Pages 2064-2068

  Ferrer, Gerardo ^a   Hodgson, Kate ^a   Pereira, Arturo ^b   Juan, Manel ^b   Elena, Montse ^b   Colomer, Dolors ^b   Roué, Gael ^b   Aymerich, Marta ^b   Baumann, Tycho ^a   Montserrat, Emili ^a   Moreno, Carol ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cytokine production and paraneoplastic conditions; Lymphoid leukemia; Prognostication

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; BETA 2 MICROGLOBULIN; CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA; PROTEIN KINASE ZAP 70;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CELL MATURATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DISEASE MARKER; FEMALE; GENDER; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; B-CELL ACTIVATING FACTOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 80054970004     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.591008     Document Type: Article

References (26)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
3. Schena M, Larsson LG, Gottardi D, et al. Growth-and differentiation- associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981-2989.
4. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989;71:343-350.
5. Mackay F, Schneider P, Rennert P, Browning J. Baffand april: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-264.
6. Planelles L, Castillo-Gutierrez S, Medema JP, Morales-Luque A, Merle-Beral H, Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 2007;92:1284-1285.
7. Th ien M, Phan TG, Gardam S, et al. Excess BAFFrescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-798.
8. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007;19:327-336.
9. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006;18:305-317.
10. Bojarska-Junak A, Hus I, Chocholska S, et al. BAFFand APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res 2009;33: 1319-1327.
11. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFFand APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006;118:281-292.
12. Molica S, Digiesi G, Mauro F, et al. Increased serum BAFF(B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leuk Res 2009;33:162-165.
13. Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24:2882-2888.
14. Molica S, Digiesi G, Battaglia C, et al. Baffserum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol 2010;85:314-320.
15. Mü ller-Hermelink HK, Montserrat E, Catovsky D, et al. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Swerdlow HS, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 180-182.
16. Monzo M, Moreno I, Artells R, et al. Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett 2006;233: 117-123.
17. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003;43:121-137.
18. Ferrer G, Hodgson K, Montserrat E, Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma 2009;50:1075-1082.
19. Endo T, Nishio M, Enzler T, et al. BAFFand APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109:703-710.
20. Kern C, Cornuel JF, Billard C, et al. Involvement of BAFFand APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-688.
21. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002;100:2973-2979.
22. Sawicka-Powierza J, Jablonska E, Kloczko J, Piszcz J, Garley M, Ratajczk-Wrona W. Evaluation of TNF superfamily molecules release by neutrophils and B leukemic cells of patients with chronic B-cell lymphocytic leukemia. Neoplasma 2011;58:45-50.
23. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-3375.
24. Guadagnoli M, Kimberley F, Phan U, et al. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood 2011 May 6. [Epub ahead of print]
25. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFFand APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012-1020.
26. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104: 2247-2253.